Pillar Biosciences Incorporated

Biotechnology ResearchMassachusetts, United States51-200 Employees

Pillar Biosciences Incorporated operates in the biotechnology research sector and focuses on Decision Medicine, using next-generation sequencing to support cancer treatment decisions, including tumor profiling, therapy selection, and recurrence monitoring. The company's NGS testing solutions are built on its SLIMamp and PiVAT technologies, designed to streamline testing, reduce costs, and improve access for clinicians, prescribers, and patients worldwide. Pillar offers more than 20 NGS testing kits in IVD or RUO formats, with several panels at various stages of development, and operates in Natick, Massachusetts. The organization has a staff of 51 to 200 employees and has pursued strategic partnerships, including a multi-year global agreement with CellCarta announced in 2026 and a 2025 collaboration with Platomics to address regulatory compliance for IVDR. It has participated in industry events such as the AMP Annual Meeting and ESMO 2025, and has additional partnerships, including a 2025 NGS automation and co-marketing partnership with Hamilton Company. Financially, Pillar reports revenue in the range of $25 million to $50 million and has raised about $35 million in funding.

Sign up for free to view info

Email Format Employee directory